Stanley B. Cohen
Impact in
- Rheumatology top 0.02%
- Rheumatoid Arthritis Research and Therapies
- Spondyloarthritis Studies and Treatments
- Osteoarthritis Treatment and Mechanisms
- Systemic Lupus Erythematosus Research
- Orthopedics and Sports Medicine top 0.2%
- Bone health and osteoporosis research
Papers in
- Rheumatology 119
- Rheumatoid Arthritis Research and Therapies 103
- Osteoarthritis Treatment and Mechanisms 8
- Systemic Lupus Erythematosus Research 4
- Spondyloarthritis Studies and Treatments 4
- Immunology 29
- Biosimilars and Bioanalytical Methods 26
- Co-authors
- John Turner Sharp (5 shared papers)Larry W. Moreland (7 shared papers)Roy Fleischmann (19 shared papers)Mark C. Genovese (15 shared papers)Ronald van Vollenhoven (7 shared papers)Paul E. Emery (16 shared papers)Alan Kivitz (23 shared papers)Michael H. Schiff (7 shared papers)
- Journals
- Annals of the Rheumatic Diseases (19 papers)Arthritis & Rheumatology (11 papers)Rheumatology and Therapy (8 papers)Lara D. Veeken (7 papers)Arthritis Care & Research (7 papers)
- Partner nations
- United StatesUnited KingdomGermany
In The Last Decade
Stanley B. Cohen
189 papers receiving 18.9k citations
Stanley B. Cohen's Hit Papers
Peers
Comparison fields: 5 of 112
- Rheumatology 9.9k
- Orthopedics and Sports Medicine 2.1k
- Immunology 1.2k
- Oncology 448
- Neurology 123
Countries citing papers authored by Stanley B. Cohen
This map shows the geographic impact of Stanley B. Cohen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stanley B. Cohen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stanley B. Cohen more than expected).
Fields of papers citing papers by Stanley B. Cohen
This network shows the impact of papers produced by Stanley B. Cohen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stanley B. Cohen. The network helps show where Stanley B. Cohen may publish in the future.
Co-authors
The 25 scholars most cited alongside Stanley B. Cohen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 193 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment Hit paper breakdown → | 2005 | 1521 |
| 2 | Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks Hit paper breakdown → | 2006 | 1382 |
| 3 | Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion Protein Hit paper breakdown → | 1997 | 1359 |
| 4 | Denosumab in Postmenopausal Women with Low Bone Mineral Density Hit paper breakdown → | 2006 | 996 |
| 5 | Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis Hit paper breakdown → | 2012 | 809 |
| 6 | Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression Hit paper breakdown → | 2004 | 769 |
| 7 | 2002 | 541 | |
| 8 | 1999 | 516 | |
| 9 | Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study Hit paper breakdown → | 2013 | 487 |
| 10 | Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve‐month, multicenter, randomized, double‐blind, placebo‐controlled, phase II clinical trial Hit paper breakdown → | 2008 | 481 |
| 11 | 2003 | 471 | |
| 12 | 2004 | 449 | |
| 13 | 2000 | 405 | |
| 14 | Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials Hit paper breakdown → | 2017 | 341 |
| 15 | 2006 | 318 | |
| 16 | 2002 | 315 | |
| 17 | 2011 | 310 | |
| 18 | Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study Hit paper breakdown → | 2019 | 299 |
| 19 | 2007 | 276 | |
| 20 | 2004 | 262 |
About Stanley B. Cohen
Stanley B. Cohen is a scholar working on Rheumatology, Immunology, Orthopedics and Sports Medicine, Toxicology and Immunology and Allergy, having authored 193 papers that have together received 20.2k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (103 papers), Biosimilars and Bioanalytical Methods (26 papers), Bone health and osteoporosis research (13 papers), Osteoarthritis Treatment and Mechanisms (8 papers), Systemic Lupus Erythematosus Research (4 papers), Spondyloarthritis Studies and Treatments (4 papers), Inflammatory Myopathies and Dermatomyositis (3 papers) and Nitric Oxide and Endothelin Effects (2 papers). The work is most often cited by research in Rheumatology (9.9k citations), Orthopedics and Sports Medicine (2.1k citations), Immunology (1.2k citations), Oncology (448 citations) and Neurology (123 citations). Stanley B. Cohen has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include John Turner Sharp, Larry W. Moreland, Roy Fleischmann, Mark C. Genovese, Ronald van Vollenhoven, Paul E. Emery, Alan Kivitz, Michael H. Schiff, Michael H. Weisman and Maria Greenwald. Their work appears in journals such as Annals of the Rheumatic Diseases, Arthritis & Rheumatology, Rheumatology and Therapy, Lara D. Veeken and Arthritis Care & Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.